Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
机构：[1]Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College &Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministryof Education, Beijing, China[2]Department of Rheumatology, Jiangsu Provincial People’s Hospital, Nanjing,Jiangsu, China江苏省人民医院[3]Department of Rheumatology, the First Affiliated Hospital of Anhui Medical University,Hefei, Anhui, China[4]Department of Rheumatology, Zhongshan Hospital Affiliated to Fudan University,Shanghai, China[5]Department of Rheumatology, the General Hospital of Tianjin Medical University, Tianjin,China[6]Department of Rheumatology, Capital Institute of Pediatrics, Beijing, China首都儿科研究所[7]Department ofRheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China中山大学附属第三医院
Objectives To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). Methods The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm(3) at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm(3). The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated. Results Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%). Conclusions Thrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia.
基金：
Chinese National Key Technology R&D Program, Chinese National High Technology Research and Development Program, Ministry of Science and Technology of People's Republic of China [2017YFC0907601, 2017YFC0907602, 2017YFC0907603, 2008BAI59B02, 2012AA02A513]
第一作者机构：[1]Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College &Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministryof Education, Beijing, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Jiang N.,Li M.,Zhang M.,et al.Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus[J].PLOS ONE.2019,14(11):doi:10.1371/journal.pone.0225516.
APA：
Jiang, N.,Li, M.,Zhang, M.,Xu, J.,Jiang, L....&Zeng, X..(2019).Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus.PLOS ONE,14,(11)
MLA：
Jiang, N.,et al."Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus".PLOS ONE 14..11(2019)
